Treatment Efficacy with Accelerated Partial Breast Irradiation (APBI): Final Analysis of the American Society of Breast Surgeons MammoSite® Breast Brachytherapy Registry Trial
- 939 Downloads
The purpose of this study was to examine data on treatment efficacy, cosmesis and toxicities for the final analysis of the American Society of Breast Surgeons MammoSite® breast brachytherapy registry trial.
A total of 1,449 cases of early-stage breast cancer underwent breast conserving therapy. The single-lumen MammoSite® device was used to deliver accelerated partial breast irradiation (APBI) (34 Gy in 3.4 Gy fractions). Of these, 1,255 cases (87 %) had invasive breast cancer (IBC) and 194 cases had DCIS. Median follow-up was 63.1 months with 45 % of all patients having follow-up of 6 years or longer.
There were 41 cases (2.8 %) that developed an ipsilateral breast tumor recurrence (IBTR) for a 5-year actuarial rate of 3.8 % (3.7 % for IBC and 4.1 % for DCIS). Tumor size (odds ratio [OR] = 1.1, p = 0.03) and estrogen receptor negativity (OR = 3.0, p = 0.0009) were associated with IBTR, while a trend was noted for positive margins (OR = 2.0, p = 0.06) and cautionary/unsuitable status compared with suitable status (OR = 1.8, p = 0.07). The percentage of patients with excellent/good cosmetic results at 60, 72, and 84 months was 91.3, 90.5, and 90.6 %, respectively. The overall rates of fat necrosis and infections remained low at 2.5 and 9.6 % with few late toxicity events beyond 2 years. The overall symptomatic seroma rate was 13.4 and 0.6 % beyond 2 years.
The final analysis of treatment efficacy, cosmesis, and toxicity from the American Society of Breast Surgeons MammoSite® breast brachytherapy registry trial confirms previously noted excellent results and compares favorably with other forms of APBI with similar follow-up and to outcomes seen in selected patients treated with whole breast irradiation.
KeywordsBreast Conserve Therapy Accelerate Partial Breast Irradiation Ipsilateral Breast Tumor Recurrence Estrogen Receptor Negativity Whole Breast Irradiation
The MammoSite® breast brachytherapy registry trial was supported in part by a Grant by Hologic, Inc., Bedford, MA. Hologic, Inc. had no access to or influence on the data, analysis, or conclusions of this paper prior to publication.
Conflict of interest
There are no conflicts of interest to declare except Martin Keisch, M.D.: Consultant/Advisory Board, Hologic, Inc., Bedford, Massachusetts.
- 2.Shah C, Antonucci JV, Wilkinson JB, Wallace M, Ghilezan M, Chen P, et al. Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol. 2011;100:210–4.PubMedCrossRefGoogle Scholar
- 4.Smith GL, Xu Y, Buchholz TA, Giordano SH, Jiang J, Shih YC, et al. Associations between treatment with brachytherapy versus whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. J Am Med Assoc. 2012;307:1827–37.CrossRefGoogle Scholar
- 8.Shaitelman SF, Vicini FA, Beitsch P, Haffty B, Keisch M, Lyden M. Five-year outcome of patients classified using the American Society for Radiation Oncology consensus statement guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite Registry Trial. Cancer. 2010;116:4677–85.PubMedCrossRefGoogle Scholar
- 13.van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92:1143–50.PubMedCrossRefGoogle Scholar
- 16.Vaidya JS, et al Targeted intraoperative radiotherapy for early breast cancer: TARGIT-a trial-updated analysis of local recurrence and first analysis of survival. SABCS. 2012; Abstract S4-2.Google Scholar
- 18.Indelicato D, Grobmyer SR, Newlin H, Morris CG, Haigh LS, Copeland EM 3rd, et al. Association between operative closure type and acute infection, local recurrence, and disease surveillance in patients undergoing breast conserving therapy for early-stage breast cancer. Surgery. 2007;141:645–53.PubMedCrossRefGoogle Scholar
- 19.Monticciolo DL, Biggs K, Gist AK, Sincleair ST, Hajdik RL, Nipper ML, et al. Breast conserving therapy with accelerated partial breast versus external beam whole breast irradiation: comparison of imaging sequela and complications in a matched population. Breast J. 2011;17:187–90.PubMedCrossRefGoogle Scholar